Strides Arcolab shares up 4% on Sun Pharma deal

Image
Press Trust of India Mumbai
Last Updated : Sep 21 2015 | 1:28 PM IST
Shares of Strides Arcolab rose by 4 per cent today as it entered into a pact with Sun Pharma to buy from it erstwhile Ranbaxy's two divisions in central nervous system (CNS) segment in India for Rs 165 crore.
The stock gained 3.98 per cent to Rs 1,191.50 at the BSE.
On the NSE, shares of Strides went up by 3.49 per cent to Rs 1,191.90.
Sun Pharma's scrip gained 0.75 per cent to Rs 911.90 but later pared the gains and was trading at Rs 899.50, down 0.62 per cent on BSE.
Sun Pharma and Strides have entered into a definitive agreement related to erstwhile Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the CNS segment in India, Strides had said in a statement on Saturday.
The agreement involves transfer of these two marketing divisions, along with employees to Strides for a consideration of Rs 165 crore, it said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 21 2015 | 1:28 PM IST

Next Story